The potential for NAFLD & NASH to overwhelm the liver transplant infrastructure in the U.S.

The episode draws the explicit analogy: hepatitis C was a silent disease that people acquired in the 70s and 80s and lived with silently until showing up with cirrhosis 20-30 years later. NAFLD follows exactly the same trajectory, but instead of a virus, the driver is metabolic dysfunction. The difference is there is no DAA-equivalent treatment for NAFLD — the slope of the transplant curve cannot currently be broken pharmacologically. This makes early metabolic intervention (weight loss, exercise, metabolic control) the only meaningful upstream lever.

The episode explicitly cites Dr. Jessica Mellinger at the University of Michigan as the leader in this reframing. Her argument: if it is a behavioral disease, the resources put forth must be behavioral resources. Transplant centers have evolved from a binary in/out sobriety model to building mental health professionals and counselors into the evaluation and support infrastructure. The guest notes this is happening in parallel with a shift in the patient population — younger, often in their 20s-30s — which makes recovery with support far more plausible than in a 65-year-old with decades of alcohol use.

The clinical framing in the episode is that the liver transplant field is experiencing a paradigm shift: they are now managing patients who look like kidney transplant patients, not classic isolated liver-disease patients. This requires importing the multi-disciplinary metabolic management model from nephrology and endocrinology into hepatology. The immunosuppression required to prevent transplant rejection adds further metabolic stress — contributing to weight gain, diabetes, hyperlipidemia, and hypertension in patients who already have all of these.

Attia's framing in the episode is pointed: the opiate crisis correctly throws manufacturers and over-prescribing physicians under the bus, but the elephant in the room is the why — the underlying conditions that drive self-medication. The same question applies to alcohol, but because alcohol produces deaths slowly and diffusely, the public health response has been far less urgent. The guest from University of Michigan who treats both hepatitis C patients and NAFLD patients and ALD patients has front-row clinical experience: he sees the end-stage outcomes of both addictions in real bodies. The chronic, invisible nature of alcohol damage is precisely why it needs more systematic clinical and policy attention, not less.

The conversation frames DAAs alongside HIV antiretrovirals as the top medical advances of their generation. The guest explicitly says he cannot think of something more impressive in his adult medical life. The key surprise was hepatic recompensation: once viremia cleared, patients' livers started repairing even when cirrhosis was already established. Patients who were pre-cirrhotic will never get there now. The result has been a precipitous, nearly complete drop in hepatitis C as a transplant indication over the past three to five years.

The episode makes the point that NAFLD was essentially unknown as a major disease 20 years prior to this recording. It has emerged alongside the obesity epidemic and is now tracking toward dominating liver transplant infrastructure. The absence of a treatment that meaningfully breaks the progression curve — as DAAs broke the hepatitis C curve — is what makes this uniquely threatening to the transplant system. The guest frames it as a kind of slow-motion crisis without an obvious pharmacologic escape valve.

The guest frames the rise in ALD as structurally parallel to the opiate crisis, but receiving less societal attention because alcohol toxicity is chronic rather than acute. Both represent people self-medicating underlying psychological distress with substances; opiates produce immediate visible deaths, while alcohol kills slowly through cirrhosis, making the epidemic less legible to the public health system. The pandemic accelerated the trend significantly. Transplant centers have shifted away from rigid sobriety gatekeeping toward building behavioral health support infrastructure to help patients succeed post-transplant.

The guest draws a direct parallel: one population numbs with an acute toxin (opiates) with acute visible toxicity; the other numbs with a chronic toxin (alcohol) with chronic invisible toxicity. The underlying condition — distress, self-medication, behavioral disease — is the same. The guest cites Dr. Jessica Mellinger at University of Michigan as a leader in formalizing this framing and pushing for behavioral health resources alongside hepatological care. Treating them as different diseases or different moral categories has, in the guest's view, slowed progress on both.

The field's clinical comment is that liver transplant programs have converted their population to look a lot more like their kidney transplant population. The comorbidities of metabolic syndrome — cardiovascular disease, hyperlipidemia, obesity-related surgical risk — threaten long-term survival as much as the liver disease itself. This demands pre-transplant cardiovascular risk stratification, careful patient selection, and post-transplant management infrastructure that liver transplant centers previously did not need. The immunosuppression required after transplant adds further metabolic burden, compounding an already-compromised metabolic picture.